SABCS

Keytruda/Chemo Combo Is ‘Great News’ for Patients With TNBC, ‘But We Need Much More’

January 6th 2022

An expert discusses improvements in survival outcomes for patients with triple-negative breast cancer who received Keytruda plus chemotherapy — now considered the standard of care — but urges that more researched is always needed for this patient population.

Aromatase Inhibitors Reduce Recurrence Risk, But Not Death Rates, in Premenopausal Patients With Breast Cancer

January 5th 2022

Premenopausal women with ER-positive breast cancer experienced a decreased rate of recurrence when given an aromatase inhibitor, compared with those given tamoxifen. However, more research is still needed, an expert said.

Novel Drug Combo Induces Encouraging Results in Patients With Heavily Pretreated Breast Cancer

January 3rd 2022

The use of Faslodex plus the investigational drug samuraciclib was considered safe in individuals with heavily pretreated hormone receptor-positive breast cancer.

Second-Line Enhertu May Be ‘Standard of Care’ for Patients with HER2-Positive Metastatic Breast Cancer

December 28th 2021

The use of Enhertu may also be beneficial across HER2-positive metastatic breast cancer subgroups including patients with and without brain metastases.

Study Results Champion Keytruda/Chemo as ‘New Standard of Care’ in TNBC Subset

December 27th 2021

The combination of Keytruda and chemotherapy improved survival rates in patients with PD-L1—positive metastatic triple-negative breast cancer.

Pre-Surgical Keytruda Provides Promising Advancement in TNBC Treatment

December 20th 2021

Findings from a clinical trial showed that adding Keytruda to neoadjuvant chemotherapy in patients with triple-negative breast cancer significantly improved outcomes and was overall safe and tolerable for patients.

Some Treatment Outcomes Do Not Differ Between Black and White Patients With Breast Cancer, But Disparities Persist

December 12th 2021

Study results showed that pathologic complete response rates were not significantly different between Black and White patients with high-risk breast cancer, but disparities still exist for other treatment outcomes.

Lynparza After Chemo May Not Greatly Impact Quality of Life in High-Risk Early Breast Cancer Subset

December 11th 2021

Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.

Triplet Regimen Extends Time Before Brain, Spinal Cord Metastases Worsen in Patients With Breast Cancer

December 10th 2021

A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.

Experimental Drug Plus Chemo Boosts Survival in HER2-Positive Metastatic Breast Cancer

December 10th 2021

The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.

Novel Drug Elicits Favorable Outcomes in Advanced, Metastatic TNBC

December 10th 2021

Early-phase study results showed that treatment with a novel drug elicits promising outcomes in patients with advanced or metastatic triple-negative breast cancer.

Immunotherapy Before Surgery May ‘Increase the Chances’ Patients Are Cured of TNBC

December 9th 2021

Clinical trial results show that adding Keytruda to chemotherapy prior to surgery for triple-negative breast cancer can improve outcomes and hopefully “increase the chances for patients to be cured,” according to an expert.

Black Patients More Likely to Experience Treatment Changes That May Worsen Breast Cancer Outcomes

December 9th 2021

Treatment modifications in the pre-surgery setting led to a lower rate of pathologic complete response in Black patients with breast cancer, the researchers found.

Study Confirms Adding Ibrance to Endocrine Therapy May Not Improve Outcomes in Early Breast Cancer

December 8th 2021

The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.

Medication Used to Treat Diabetes Fails to Improve Breast Cancer Outcomes

December 8th 2021

Researchers hypothesized that metformin — a medication that helps lower insulin levels in patients with diabetes and is associated with inducing weight loss — might improve breast cancer outcomes.

Novel Drug Has Potential to ‘Become New Standard of Care’ in Advanced, ER-Positive Breast Cancer

December 8th 2021

The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

Novel Drug Combo Doubles Progression-Free Survival in HER2-Negative Metastatic Breast Cancer

December 7th 2021

Ibrance plus Faslodex improved progression-free survival in certain patients with metastatic breast cancer, compared with those who continued to receive an aromatase inhibitor.

Black Women With Breast Cancer Have a Higher Risk of Developing Lymphedema Than White Women

December 7th 2021

Black race is associated with a 3.5-fold increased incidence of lymphedema in women with breast cancer treated with axillary lymph node dissection and radiotherapy, according to recent data.

Keytruda and Chemotherapy Combination Broadens Number of Treatable Patients with TNBC

January 8th 2021

In an interview with CURE®, lead study investigator of the Keynote 355 trial, Dr. Hope S Rugo, discusses the results of the study that led to the FDA approval of the combination therapy and what further data means for certain patients with metastatic triple-negative breast cancer.

Novel Therapy Continues to Show Prolonged, Durable Responses and Survival Outcomes in Patients with HER2-Positive Metastatic Breast Cancer

December 17th 2020

Updated data from the phase 2 DESTINY-Breast01 study continues to show encouraging and durable responses for patients with HER2-positive metastatic breast cancer.

Patients Who Experienced Chemotherapy-Induced Nausea/Vomiting During First Cycle of Cancer Treatment May Be at Greater Risk for Recurrence of the Side Effect

December 12th 2020

Approximately half of the patients with breast cancer who failed anti-nausea or vomiting therapy for chemotherapy-induced nausea/vomiting during their first cycle of treatment failed to avoid the side effect at some point during the next three treatment cycles.

Tesetaxel with Reduced Dose of Xeloda Improves Progression-Free Survival in Breast Cancer

December 12th 2020

Tesetaxel, a novel agent, with Xeloda contributed to a median progression-free survival of 9.8 months, compared with 6.9 months with Xeloda alone, in patients with metastatic breast cancer.

Chemotherapy With Endocrine Therapy Shows Clinical Benefit With Improved Survival in Breast Cancer

December 12th 2020

Premenopausal women with HR-positive, HER2-negative, lymph node-positive breast cancer and a risk for recurrence experienced benefits with chemotherapy plus endocrine therapy, with improvements in five-year invasive disease-free and overall survival.

Side Effects from Oral Paclitaxel Plus Encequidar May Be Mitigated with Anti-Nausea Medications, Loperamide

December 11th 2020

An increase in gastrointestinal side effects were found with the more effective combination of oral paclitaxel and encequidar; however, new safety evaluations demonstrated that various antiemetics can help treat these effects in patients with metastatic breast cancer.

Verzenio Continues to Show Reduced Risk in Invasive Disease-Free Survival in High-Risk Early HR+ Breast Cancer

December 11th 2020

In this phase 3 trial, Verzenio with endocrine therapy reduced the risk for invasive disease recurrence and death versus endocrine therapy alone for patients with high-risk, early hormone receptor–positive, HER2-negative breast cancer.

Breast Cancer Survivors May Have Difficulty Becoming Pregnant, But Have Healthy Babies and Experience No Impact on Long-Term Survival

December 11th 2020

While breast cancer survivors had a 45% higher risk of going into preterm labor, there were no significant increased risks of congenital defects or other pregnancy or delivery complications.

Meditation, Survivorship Classes Significantly Reduced Depressive Symptoms in Young Breast Cancer Survivors

December 10th 2020

Prior to receiving behavioral interventions, more than half of participating young survivors of breast cancer were considered clinically depressed. That number dropped to 30% after participants received mindfulness meditation and survivorship education classes.

Dietary Changes to Reduce Diabetes Risk May Also Increase Survival for Breast Cancer

December 10th 2020

Women with higher diet adherence scores after diagnosis had a 33% lower risk for all-cause mortality and a 17% lower risk for mortality related to breast cancer compared with women with lower diet adherence scores.

Physicians ‘Systematically’ Miss Substantial Symptoms in Certain Patients With Breast Cancer

December 10th 2020

Of note, the results indicated that patients with breast cancer who were younger than 60 and of Black or other race were more likely to experience under-recognized symptoms by their physician.

Oral Paclitaxel-Encequidar Combo Appears Safe, Effective in Patients With Rare Subset of Breast Cancer

December 9th 2020

Recently presented data demonstrated that a combination of oral paclitaxel and Encequidar elicited promising results in patients with radiation-associated breast angiosarcoma.

NEXT PAGE
PREVIOUS PAGE